文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

LiquidArray MTB-XDR VER 1.0 检测结核分枝杆菌复合群及氟喹诺酮、阿米卡星、乙胺丁醇和利奈唑胺敏感性的诊断准确性

Diagnostic Accuracy of LiquidArray MTB-XDR VER 1.0 for the Detection of Mycobacterium tuberculosis Complex, Fluoroquinolone, Amikacin, Ethambutol, and Linezolid Susceptibility.
PubMed 文献 · Clin Infect Dis · 2025-01-01

研究纳入720例疑似结核患者,评估LiquidArray MTB-XDR检测结核分枝杆菌复合群及四种药物敏感性的准确性。该检测对氟喹诺酮和乙胺丁醇耐药敏感性高,阿米卡星耐药敏感性中等,利奈唑胺耐药检测有前景但需更多数据。

要点

  • LA-XDR检测MTBC敏感性85%-87%,特异性99%。
  • 氟喹诺酮耐药敏感性94%,乙胺丁醇88%,阿米卡星64%。
  • fleXT提取时利奈唑胺不确定比例高达37%。

核心结论

  • LA-XDR满足世界卫生组织对下一代痰基中等复杂度药敏试验的最低目标产品概况,氟喹诺酮和乙胺丁醇耐药敏感性高,阿米卡星耐药敏感性中等,利奈唑胺耐药检测有前景但需更多数据。
  • 改进LA-XDR的MTBC检测可减少漏检耐药。

研究设计与样本

  • 研究纳入720例疑似结核患者,每人提供2份痰标本进行Xpert MTB/RIF Ultra检测和培养(MTBC参考标准)。
  • 表型药敏试验和Sanger测序作为复合参考标准。
  • 比较手动FluoroLyse和自动GenoXtract fleXT两种DNA提取方法上的LA-XDR检测。

主要发现

  • 对于MTBC,LA-XDR在每种提取方法下敏感性相似(85%-87%),特异性99%。
  • 药物敏感性敏感性(95%CI):氟喹诺酮94%(86%-98%),阿米卡星64%(45%-80%),乙胺丁醇88%(79%-93%),特异性97%-100%。
  • 7株利奈唑胺耐药分离株中检测到6株(86%)。
  • fleXT提取时LA-XDR不确定比例:氟喹诺酮21/251(8%),乙胺丁醇2/251(1%),阿米卡星63/251(25%),利奈唑胺93/251(37%);阿米卡星和利奈唑胺不确定比例在FluoroLyse提取DNA时更高。
  • 在100例涂片阴性氟喹诺酮耐药结核患者的假设人群中,采用fleXT DNA提取时25例(25%)会被漏检(1例提取错误,2例无效结果,15例MTBC阴性,6例氟喹诺酮不确定,1例假敏感)。

局限性

  • 利奈唑胺耐药检测需要更多数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug susceptibility testing (DST) is essential for starting people on effective tuberculosis (TB) regimens. No published data exist for the high-throughput LiquidArray MTB-XDR (LA-XDR) test, which detects Mycobacterium tuberculosis complex (MTBC) and fluoroquinolone, amikacin, ethambutol, and linezolid susceptibility (the latter 2 have no rapid DSTs available). METHODS: We enrolled people (N = 720) with presumptive TB who provided 2 sputum samples for an Xpert MTB/RIF Ultra assay and a culture (MTBC reference standard). Phenotypic DST and Sanger sequencing were the composite reference standards. LA-XDR on the manual FluoroLyse and automated GenoXtract fleXT (fleXT) DNA extraction methods were compared. RESULTS: For MTBC, LA-XDR had similar sensitivities (85%-87%) and specificities (99%) using each extraction method. Drug susceptibility sensitivities (95% confidence interval) varied: 94% (86%-98%) for fluoroquinolones, 64% (45%-80%) for amikacin, and 88% (79%-93%) for ethambutol (specificities of 97%-100%). Six of 7 (86%) resistant linezolid isolates were detected. LA-XDR with fleXT had indeterminate proportions of 21/251 (8%), 2/251 (1%), 63/251 (25%), and 93/251 (37%) for fluoroquinolones, ethambutol, amikacin, and linezolid, respectively (amikacin and linezolid indeterminates were higher with FluoroLyse-extracted DNA). In a hypothetical population of 100 smear-negative people with fluoroquinolone-resistant TB undergoing fleXT DNA extraction, 25 (25%) would be missed (1 extraction error, 2 invalid results, 15 MTBC-negative, 6 fluoroquinolone-indeterminate, and 1 false-susceptible). CONCLUSIONS: LA-XDR met the minimum World Health Organization target product profile for a next-generation, sputum-based, moderate-complexity DST with high fluoroquinolone and ethambutol resistance sensitivity, moderate amikacin resistance sensitivity, and promise for linezolid resistance, for which more data are needed. Improved LA-XDR MTBC detection would reduce missed resistance.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Auma E, Alberts R, Derendinger B, et al. Diagnostic Accuracy of LiquidArray MTB-XDR VER 1.0 for the Detection of Mycobacterium tuberculosis Complex, Fluoroquinolone, Amikacin, Ethambutol, and Linezolid Susceptibility. Clin Infect Dis. 2025. PMID: 39663850. doi:10.1093/cid/ciae614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。